Mark Manfredi

7.0k total citations · 1 hit paper
57 papers, 3.7k citations indexed

About

Mark Manfredi is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Mark Manfredi has authored 57 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 25 papers in Cell Biology and 24 papers in Oncology. Recurrent topics in Mark Manfredi's work include Microtubule and mitosis dynamics (24 papers), Cancer-related Molecular Pathways (12 papers) and Ubiquitin and proteasome pathways (11 papers). Mark Manfredi is often cited by papers focused on Microtubule and mitosis dynamics (24 papers), Cancer-related Molecular Pathways (12 papers) and Ubiquitin and proteasome pathways (11 papers). Mark Manfredi collaborates with scholars based in United States, Japan and United Kingdom. Mark Manfredi's co-authors include Jeffrey Ecsedy, Jessica J. Huck, Mengkun Zhang, Joseph B. Bolen, Alexander J. Muller, George C. Prendergast, Yousef Zakharia, Kara M. Hoar, Corinne Reimer and Surender Kharbanda and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Mark Manfredi

56 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

2020 335 citations Luís Felipe Campesato, Sadna Budhu et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Manfredi United States	24	2.2k	1.3k	1.0k	540	529	57	3.7k
Natalia Shpiro United Kingdom	26	4.3k 2.0×	970 0.7×	742 0.7×	755 1.4×	581 1.1×	36	5.8k
Shalom Avraham United States	45	3.4k 1.6×	1.7k 1.3×	847 0.8×	1.1k 2.1×	618 1.2×	89	6.2k
Claudio Brancolini Italy	40	3.4k 1.6×	839 0.6×	763 0.8×	1.1k 2.0×	386 0.7×	103	5.1k
Quentin Liu China	47	3.7k 1.7×	1.7k 1.3×	1.3k 1.2×	532 1.0×	1.5k 2.9×	163	6.1k
Adriana Bajetto Italy	36	1.6k 0.8×	1.9k 1.5×	207 0.2×	1.4k 2.5×	459 0.9×	65	4.3k
Antonella Isacchi Italy	29	1.9k 0.9×	586 0.4×	432 0.4×	330 0.6×	289 0.5×	84	2.8k
Jordan S. Fridman United States	22	3.6k 1.7×	2.0k 1.5×	222 0.2×	700 1.3×	679 1.3×	41	6.0k
Kevin M. Haigis United States	42	3.9k 1.8×	2.5k 1.9×	713 0.7×	609 1.1×	1.0k 1.9×	105	6.8k
Ashani T. Weeraratna United States	40	3.9k 1.8×	1.8k 1.4×	916 0.9×	1.1k 2.0×	1.1k 2.0×	114	6.6k
Dmitry V. Bulavin United States	38	4.2k 1.9×	2.2k 1.7×	867 0.9×	634 1.2×	1.0k 1.9×	58	5.7k

Countries citing papers authored by Mark Manfredi

Since Specialization

Citations

This map shows the geographic impact of Mark Manfredi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Manfredi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Manfredi more than expected).

Fields of papers citing papers by Mark Manfredi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Manfredi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Manfredi. The network helps show where Mark Manfredi may publish in the future.

Co-authorship network of co-authors of Mark Manfredi

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Manfredi. A scholar is included among the top collaborators of Mark Manfredi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Manfredi. Mark Manfredi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGovern, Karen, Alfredo Castro, Jill Cavanaugh, et al.. (2022). Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression. Molecular Cancer Therapeutics. 21(8). 1261–1272. 27 indexed citations

Campesato, Luís Felipe, Sadna Budhu, Jeremy H. Tchaicha, et al.. (2020). Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications. 11(1). 4011–4011. 335 indexed citations breakdown →

Gallery, Melissa, Daniel P. Bradley, Pamela P. Brauer, et al.. (2018). A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo. PLoS ONE. 13(1). e0191046–e0191046. 20 indexed citations

Muller, Alexander J., Mark Manfredi, Yousef Zakharia, & George C. Prendergast. (2018). Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology. 41(1). 41–48. 197 indexed citations

Huck, Jessica J., Mengkun Zhang, Jerome T. Mettetal, et al.. (2014). Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics. 13(9). 2170–2183. 27 indexed citations

Palani, Santhosh, Jessica J. Huck, Mengkun Zhang, et al.. (2013). Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemotherapy and Pharmacology. 72(6). 1255–1264. 19 indexed citations

Dees, Elizabeth Claire, Roger B. Cohen, Margaret von Mehren, et al.. (2012). Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research. 18(17). 4775–4784. 128 indexed citations

Shinde, Vaishali, Bradley Stringer, Mark G. Qian, et al.. (2012). MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma. Molecular Cancer Therapeutics. 11(9). 2045–2053. 16 indexed citations

Manfredi, Mark, Jeffrey Ecsedy, Arijit Chakravarty, et al.. (2011). Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays. Clinical Cancer Research. 17(24). 7614–7624. 242 indexed citations

10.

Bannerman, Bret, Ling Xu, Matthew D. Jones, et al.. (2011). Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemotherapy and Pharmacology. 68(5). 1145–1154. 32 indexed citations

11.

Kupperman, Erik, Edmund C. Lee, Yueying Cao, et al.. (2010). Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer. Cancer Research. 70(5). 1970–1980. 409 indexed citations

12.

Dees, Elizabeth Claire, Jeffrey R. Infante, Roger B. Cohen, et al.. (2010). Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(4). 945–954. 64 indexed citations

13.

Sells, Todd B., Jeffrey Ecsedy, Stephen G. Stroud, et al.. (2008). MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. Cancer Research. 68. 237–237. 14 indexed citations

14.

Huck, Jessica J., Arijit Chakravarty, Yu Li, et al.. (2007). Preclinical PK/PD/Efficacy relationship of MLN8054, a small molecule Aurora A kinase inhibitor. Molecular Cancer Therapeutics. 6. 2 indexed citations

15.

Huck, Jessica J., Mengkun Zhang, Olga Burenkova, et al.. (2006). Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor. Cancer Research. 66. 1104–1104. 8 indexed citations

16.

Manfredi, Mark, Jeffrey Ecsedy, Kristan Meetze, et al.. (2006). MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials. Cancer Research. 66. 1110–1110. 5 indexed citations

17.

El‐Abbadi, Mohga, et al.. (2001). N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. British Journal of Cancer. 84(8). 1107–1114. 40 indexed citations

18.

Maeshima, Yohei, Udaya Yerramalla, Mohanraj Dhanabal, et al.. (2001). Extracellular Matrix-derived Peptide Binds to αvβ3 Integrin and Inhibits Angiogenesis. Journal of Biological Chemistry. 276(34). 31959–31968. 174 indexed citations

19.

Maeshima, Yohei, Mark Manfredi, Corinne Reimer, et al.. (2001). Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin. Journal of Biological Chemistry. 276(18). 15240–15248. 179 indexed citations

20.

Mehta, Shashi, et al.. (1997). Taxol Pretreatment of Tumor Targets Amplifies Natural Killer Cell Mediated Lysis. Leukemia & lymphoma. 26(1-2). 67–76. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact